Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Big Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic Cancer

2.

Low PSA May Not Fully Predict Survival in Prostate Cancer

3.

Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study

4.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

5.

Single-dose radiation before surgery can eradicate breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot